Literature DB >> 15461678

fMRI of generalized absence status epilepticus in conscious marmoset monkeys reveals corticothalamic activation.

Jeffrey R Tenney1, Paul C Marshall, Jean A King, Craig F Ferris.   

Abstract

PURPOSE: A nonhuman primate model of generalized absence status epilepticus was developed for use in functional magnetic resonance imaging (fMRI) experiments to elucidate the brain mechanisms underlying this disorder.
METHODS: Adult male marmoset monkeys (Callithrix jacchus) were treated with gamma-butyrolactone (GBL) to induce prolonged absence seizures, and the resulting spike-wave discharges (SWDs) were analyzed to determine the similarity to the 3-Hz SWDs that characterize the disorder. In addition, blood-oxygenation-level-dependent (BOLD) fMRI was measured at 4.7 Tesla after absence seizure induction with GBL.
RESULTS: Electroencephalographic recordings during imaging showed 3-Hz SWDs typical of human absence seizures. This synchronized EEG pattern started within 15 to 20 min of drug administration and persisted for >60 min. In addition, pretreatment with the antiepileptic drug, ethosuximide (ESM), blocked the behavioral and EEG changes caused by GBL. Changes in BOLD signal intensity in the thalamus and sensorimotor cortex correlated with the onset of 3-Hz SWDs. The change in BOLD signal intensity was bilateral but heterogeneous, affecting some brain areas more than others. No significant negative BOLD changes were seen.
CONCLUSIONS: The BOLD fMRI data obtained in this marmoset monkey model of absence status epilepticus shows activation within the thalamus and cortex.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15461678     DOI: 10.1111/j.0013-9580.2004.21504.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  22 in total

1.  Functional neuroimaging of spike-wave seizures.

Authors:  Joshua E Motelow; Hal Blumenfeld
Journal:  Methods Mol Biol       Date:  2009

2.  Rhythmic 3-4Hz discharge is insufficient to produce cortical BOLD fMRI decreases in generalized seizures.

Authors:  Mark W Youngblood; William C Chen; Asht M Mishra; Sheila Enamandram; Basavaraju G Sanganahalli; Joshua E Motelow; Harrison X Bai; Flavio Frohlich; Alexandra Gribizis; Alexis Lighten; Fahmeed Hyder; Hal Blumenfeld
Journal:  Neuroimage       Date:  2015-01-03       Impact factor: 6.556

3.  Mapping resting-state brain networks in conscious animals.

Authors:  Nanyin Zhang; Pallavi Rane; Wei Huang; Zhifeng Liang; David Kennedy; Jean A Frazier; Jean King
Journal:  J Neurosci Methods       Date:  2010-04-09       Impact factor: 2.390

4.  NPY signaling through Y1 receptors modulates thalamic oscillations.

Authors:  Julia Brill; Gunnar Kwakye; John R Huguenard
Journal:  Peptides       Date:  2006-12-29       Impact factor: 3.750

Review 5.  Epilepsy in nonhuman primates.

Authors:  Leah Croll; Charles A Szabo; Noha Abou-Madi; Orrin Devinsky
Journal:  Epilepsia       Date:  2019-06-17       Impact factor: 5.864

Review 6.  Anatomical and functional neuroimaging in awake, behaving marmosets.

Authors:  Afonso C Silva
Journal:  Dev Neurobiol       Date:  2016-10-21       Impact factor: 3.964

7.  Novel imaging technology and procedures for studying brain function in preadolescent awake marmosets.

Authors:  Toni E Ziegler; Praveen Kulkarni; Hayley Ash; Xuezhu Cai; M Elizabeth Mayerand; Beth Rauch; Craig F Ferris
Journal:  J Neurosci Methods       Date:  2020-06-21       Impact factor: 2.390

8.  An embedded four-channel receive-only RF coil array for fMRI experiments of the somatosensory pathway in conscious awake marmosets.

Authors:  Daniel Papoti; Cecil Chern-Chyi Yen; Julie B Mackel; Hellmut Merkle; Afonso C Silva
Journal:  NMR Biomed       Date:  2013-05-22       Impact factor: 4.044

Review 9.  Epileptic networks studied with EEG-fMRI.

Authors:  Jean Gotman
Journal:  Epilepsia       Date:  2008       Impact factor: 5.864

Review 10.  The role of the basal ganglia in the control of seizure.

Authors:  J Vuong; Annaelle Devergnas
Journal:  J Neural Transm (Vienna)       Date:  2017-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.